Immunoblot analysis of SpiD3-treated primary CLL cells revealed reduced expression of NFκB proteins (p65, RELB), cell survival signaling (p-PRAS/PRAS), and proliferation factors (MYC). The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.